To investigate the immune-stimulatory effects of targeted degradation of KRASG12V in vivo, we profiled phenotypic and functional alterations of CD8+ T cells following a 5-day treatment with either vehicle or dTAGV-1 in tumor-bearing mice (Figure 5A). This evidence concerns the gene CD8A and neoplasm.